Analysis Topic: Companies AnalysisThe analysis published under this topic are as follows.
Tuesday, December 31, 2013
The best time to buy cheap is when you are afraid to bring up your ideas around the water cooler at work for fear of the peer laughter. Our work centers on looking for oversold conditions and crowd behavioral anomalies that can give us better low risk entries with good upside potential. A combination of fundamentals and technical, combined with Elliott Wave Theory patterns can lead to nice profits with low risk.
For just a few quick ideas that would make sense in this area, we point out 3 ETF’s that you could look at entering now as they are way out of favor and very oversold.Read full article... Read full article...
Monday, December 30, 2013
One can never read tomorrow's news today, but developing market activity can give one a higher degree of probability as to what, if not tomorrow's then what the news will soon be sometime after. Facebook is a case in point. The Guardian ran an article on Friday, the 27th, giving an author's opinion that Facebook "is dead and buried to teens." If one were long that stock, the level of concern should run to high alert, for Facebook has no product, other than a social venue, and social "values" can change quickly, especially among teens.
Does a market send a message to exit from a position? We say a resounding Yes! There may be some room as to when, but if there is some kind of red flag alert, then one should have a set of rules in place to protect against potential adversity. Is Facebook sending such an alert? You be the judge.
Thursday, December 26, 2013
Shah Gilani writes: Sure, the Herbalife game that pitted Bill Ackman against David Einhorn, Dan Loeb, Carl Icahn, and the rest of the billionaire boys' club was a tad bit personal.
It was also professional, very professional.
All the billionaires playing the Herbalife game are professional money managers. They made their mega fortunes in the markets.Read full article... Read full article...
Thursday, December 26, 2013
Coming of Age: Experts Reflect on the Extraordinary Promise of the Cell Therapy Sector / Companies / BioTech
Without innovation and risk-taking, modern medicine would be missing staples of the physician's armamentarium: antibiotics, radiation therapies, vaccines. The idea of taking a tonic to cure what ails you is thousands of years old, but the science behind that tonic may be revolutionary. Enter stem cell technologies. Given the promise backing the science—and the sector's position on the cusp of breaking out—companies with cell therapies got plenty of attention from investment analysts and experts in 2013. Read what those experts, including George Zavoico of MLV & Co., Steve Brozak of WBB Securities, Jason Kolbert of the Maxim Group, and Kevin DeGeeter of Ladenberg Thalmann & Co., had to say about prospects for stem cell companies in this special retrospective article from The Life Sciences Report.Read full article... Read full article...
Tuesday, December 24, 2013
If I asked you to name the biggest online shopping day of the year, what would you guess? Black Friday? Cyber Monday? Free Shipping Day in mid-December?
Even though Cyber Monday sales were spectacular this year, as online sales surged 20 percent and beat Black Friday receipts, the day didn't top November 11, Singles' Day in China. Singles' Day is a day of celebration for people who are single and has become popular among the young in China.Read full article... Read full article...
Thursday, December 19, 2013
Michael Lombardi writes:
I keep telling you about my suspicion that the backbone of any stock market—corporate earnings growth—is disappearing. Now, we see it in the numbers…
Of the 106 companies in the S&P 500 that have issued corporate earnings guidance for the fourth quarter, an astounding 94 of them have issued negative guidance—that’s 89% of the companies issuing guidance, warning it will be negative, which is well above the five-year average rate of 63%. (Source: FactSet, December 13, 2013.)
Tuesday, December 17, 2013
Shah Gilani writes: There's a lucrative new trading "set-up" a lot of investors are using now. But unlike classic approaches, like "don't fight the Fed," and "the trend is your friend," there are no rules on how to play this new game.
So let's change that today.
This is the true story about two billionaires' egos, their trading games, and what happens when they clash over the same stock.Read full article... Read full article...
Saturday, December 14, 2013
In a person with diabetes, the insulin producing beta cells in the pancreas are attacked by the immune system and destroyed, this leads to a deficiency of insulin and high blood sugar (glucose).
People with insulin-dependent diabetes (all of type-1 and about 27 percent of type-2 diabetics) lack the necessary amount of insulin in their bloodstreams. This can, and often does lead to irreversible damage to their hearts, blood vessels, eyes, kidneys, skin, feet and hearing.Read full article... Read full article...
Friday, December 13, 2013
John Paul Whitefoot writes: When it comes to building a balanced portfolio, investors like to find stocks that provide both value and growth. If you’re a value investor, you’re always on the lookout for companies that are cheap relative to their earnings, assets, or price-to-book value; in other words, they look for what’s undervalued.
A growth investor, on the other hand, likes to look at publicly traded companies that are in a position to rapidly increase their revenues and profits; they want stocks with excellent long-term growth potential. This could include those stocks that have provided revenue and earnings guidance that is expected to outperform the market or industry.Read full article... Read full article...
Friday, December 13, 2013
Get ready for a bonanza of biotech names. Managing Director and Equity Research Analyst Reni "Ren" Benjamin is a new arrival at H.C. Wainwright & Co., and he's busy doing diligence on a lot of stocks. Along with three Buy-rated biotechs he's already initiated coverage on, Benjamin brought The Life Sciences Report a bonus package of names that could fatten investors' portfolios. Backed by Benjamin's extensive industry knowledge, this long shopping list includes companies poised to make drug development history.
The Life Sciences Report: Do you currently have a major theme, Ren, or do you just go anywhere to find growth?Read full article... Read full article...
Thursday, December 12, 2013
Michael A. Robinson writes: Thanks to two huge product rollouts in November, this holiday season will be one of the hottest ever for this massive slice of the high-tech sector.
That's because three giant companies are fighting it out - to the death - for the biggest piece of a $93 billion windfall.
And investors who identify the winner of this battle stand to pull down a hefty profit.Read full article... Read full article...
Tuesday, December 10, 2013
I know that what you'll encounter in today's Outside the Box is not macroeconomics. But we all have to live in the real world, and our health is as real as it gets. So this is just one guy telling his friends about something he found that has helped make his world a lot better.
My friend and colleague Pat Cox is always finding something new and different. When Pat first introduced me to this idea, I thought he was being a little over the top. But I happened to be in Palo Alto the following week and met with the scientists Pat mentioned and saw their results. Then I got a beta unit and used it for the first time on my last birthday last year.Read full article... Read full article...
Monday, December 09, 2013
Michael A. Robinson writes: If you’ve been following our twice weekly conversations here at Strategic Tech Investor, you know that I’m very bullish about technology stocks.
But I want to let you in on a little secret …
I’m also bullish about the overall stock market.Read full article... Read full article...
Sunday, December 08, 2013
We advocate a proactive stance in managing one’s stock portfolio as the most prudent way to preserve and grow capital, by capturing gains and limiting risks. The days of buy and hold are finished, at this stage of a central bank propped-up market, fed by fiat and highly questionable reports issued by the Bureau of Lies, which seems an accurate assessment.
There are several charts to be shown, and where a picture may be worth 1,000 words, we can limit we say and defer to what the market has to say. After all, the market is the best source and always the final arbiter.Read full article... Read full article...
Thursday, December 05, 2013
George Leong writes: I pushed the “go” button on China a long time ago now, and I’m certainly not set to press “stop” yet, as I continue to feel the country is one of the top growth areas for investors worldwide. My contentions are contrary to those of many other analysts in the stock market, but I’m holding onto my bullish views.Read full article... Read full article...